Literature DB >> 30476135

Diagnosis and Management of Pediatric Influenza in the Era of Rapid Diagnostics.

Eimear Kitt1,2,3, Richard J Drew4,5,6, Robert Cunney4, Susan E Beekmann7, Philip Polgreen7, Karina Butler4,8, Theoklis Zaoutis1,2,3, Susan E Coffin1,2,3.   

Abstract

Influenza is a significant cause of childhood morbidity and death; it contributes to up to 16% of hospitalizations for respiratory illnesses worldwide. Novel rapid viral diagnostic tests, including molecular diagnostic tests, have the potential to significantly affect both time to diagnosis and selection of optimal anti-infective therapy. However, little is known about current treatment algorithms used in US hospitals. In this study, for hospitalized children in the United States, we aimed to define the current approaches to influenza diagnosis and treatment and to explore reasons for their potential variation. In this study, we aimed to define the current approaches to pediatric influenza diagnosis and treatment in US hospitals, and to explore reasons for their potential variation. Our results suggest a rise in the availability and use of rapid molecular diagnostic testing in addition to continued variability in anti-infective management, particularly with regard to antiviral use.
© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antimicrobial stewardship; diagnostic algorithm; influenza; oseltamivir; pediatric

Mesh:

Substances:

Year:  2020        PMID: 30476135     DOI: 10.1093/jpids/piy118

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  1 in total

1.  Antibiotic utilization in hospitalized children under 2 years of age with influenza or respiratory syncytial virus infection - a comparative, retrospective analysis.

Authors:  Cihan Papan; Meike Willersinn; Christel Weiß; Michael Karremann; Horst Schroten; Tobias Tenenbaum
Journal:  BMC Infect Dis       Date:  2020-08-17       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.